Nabriva Therapeutics Plc (NBRV)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

56 FITZWILLIAM SQUARE DUBLIN, IRELAND 2

Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA® (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP). Nabriva Therapeutics is also developing CONTEPO™ (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis. Nabriva entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO® (tedizolid phosphate) in the United States and certain of its territories.

Data as of 2021-10-09 10:20:57 -0400
Market Cap55.21 Million Shares Outstanding49.739 Million Avg 30-day Volume712.602 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS0
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE-0.98 Enterprise Value
Total Cash Current Debt Gross Profit
BETA1.21632 52-week High/Low6.19 / 1.0 Next Earnings Date2021-11-04 Price to Cash FLow (P/CF) -48.3597
Data provided by IEX Cloud
View SEC Filings from NBRV instead.

View recent insider trading info

Funds Holding NBRV (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding NBRV BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

50 Thousand total shares from 1 transactions

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

SCHROEDER THEODORE R CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
226,543 2021-10-06 20

GELONE STEVEN P. PRESIDENT AND COO

  • Officer
  • Director
366,506 2021-10-06 20

GUICO-PABIA CHRISTINE J. CHIEF MEDICAL OFFICER

  • Officer
0 2021-10-01 1

NAFTZGER J. CHRISTOPHER GENERAL COUNSEL AND CORP SEC

  • Officer
100,000 2021-09-30 2

CROTTY ROBERT GEN COUNSEL & CORP SECRETARY

  • Officer
41,194 2021-08-31 16

BURGESS DANIEL D

  • Director
21,725 2021-08-02 2

BROOM COLIN MD

  • Director
41,862 2021-08-02 2

ROWLAND CHARLES A JR

  • Director
23,773 2021-08-02 2

WEBSTER STEPHEN W

  • Director
19,273 2021-08-02 2

BOURDOW CARRIE L.

  • Director
18,473 2021-08-02 2

CORRIGAN MARK

  • Director
52,500 2021-07-28 3

DALTON LISA

  • Director
53,000 2021-07-28 3

DOLAN DANIEL CHIEF FINANCIAL OFFICER

  • Officer
100,000 2021-03-31 2

SENDER GARY CHIEF FINANCIAL OFFICER

  • Officer
20,472 2021-02-28 5

SCHRANZ JENNIFER CHIEF MEDICAL OFFICER

  • Officer
39,125 2021-02-28 5

LAVINO FRANCESCO MARIA CHIEF COMMERCIAL OFFICER

  • Officer
185,393 2020-09-30 0

TALBOT GEORGE HARRISON

  • Director
65,140 2020-07-29 0

VIVO CAPITAL VIII, LLC

  • 10% Owner
4,074,190 2017-09-18 0

HBM HEALTHCARE INVESTMENTS (CAYMAN) LTD.

  • 10% Owner
No longer subject to file 2017-09-12 0

KHUONG CHAU QUANG

  • Director
  • 10% Owner
3,919,600 2017-06-23 0

SELTZER ELYSE G. CHIEF MEDICAL OFFICER

  • Officer
2,400 2017-06-23 0

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP V LLC

ISALY SAMUEL D

  • Director
  • 10% Owner
391,960 2016-12-30 0

WOLF JOHN PETER III GENERAL COUNSEL AND CORP. SEC.

  • Officer
270 2016-12-30 0

BOLTE AXEL

  • Director
0 2016-12-30 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

SCHROEDER THEODORE R - Director - Officer CHIEF EXECUTIVE OFFICER

2021-10-08 16:39:59 -0400 2021-10-06 F 225 $1.08 d 226,543 direct 4.5045 4.5045 2 0.0 1

GELONE STEVEN P. - Director - Officer PRESIDENT AND COO

2021-10-08 16:41:19 -0400 2021-10-06 F 92 $1.08 d 366,506 direct 4.5045 4.5045 2 0.0 1

SCHROEDER THEODORE R - Director - Officer CHIEF EXECUTIVE OFFICER

2021-10-04 16:14:40 -0400 2021-09-30 F 107 $1.19 d 226,768 direct -0.9174 6.422 6.422 6 -0.9174 2

GELONE STEVEN P. - Director - Officer PRESIDENT AND COO

2021-10-04 16:09:54 -0400 2021-09-30 F 63 $1.19 d 366,598 direct -0.9174 6.422 6.422 6 -0.9174 2

NAFTZGER J. CHRISTOPHER - Officer GENERAL COUNSEL AND CORP SEC

2021-10-01 16:06:38 -0400 2021-09-30 A 100,000 a 100,000 direct

SCHROEDER THEODORE R - Director - Officer CHIEF EXECUTIVE OFFICER

2021-09-15 20:00:20 -0400 2021-09-14 P 50,000 $1.13 a 226,875 direct 0.0 5.2174 5.2174 6 -2.6087 3

SCHROEDER THEODORE R - Director - Officer CHIEF EXECUTIVE OFFICER

2021-09-08 17:27:25 -0400 2021-09-06 F 225 $1.11 d 176,875 direct 0.0 2.6786 2.6786 6 -5.3571 5

GELONE STEVEN P. - Director - Officer PRESIDENT AND COO

2021-09-08 17:25:44 -0400 2021-09-06 F 93 $1.11 d 366,661 direct 0.0 2.6786 2.6786 6 -5.3571 5

GELONE STEVEN P. - Director - Officer PRESIDENT AND COO

2021-09-02 16:09:28 -0400 2021-08-31 F 63 $1.06 d 366,754 direct -2.7027 0.0 0.9009 3 -2.7027 2

CROTTY ROBERT - Officer GEN COUNSEL & CORP SECRETARY

2021-09-02 16:06:35 -0400 2021-08-31 F 37 $1.06 d 41,194 direct -2.7027 0.0 0.9009 3 -2.7027 2

SCHROEDER THEODORE R - Director - Officer CHIEF EXECUTIVE OFFICER

2021-09-02 16:07:56 -0400 2021-08-31 F 107 $1.06 d 177,100 direct -2.7027 0.0 0.9009 3 -2.7027 2

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
NABRIVA THERAPEUTICS PLC NBRV 2021-10-15 22:15:04 UTC -9.8484 9.9184 1100000
NABRIVA THERAPEUTICS PLC NBRV 2021-10-15 21:45:03 UTC -9.8453 9.9153 1100000
NABRIVA THERAPEUTICS PLC NBRV 2021-10-15 21:15:03 UTC -9.8453 9.9153 1100000
NABRIVA THERAPEUTICS PLC NBRV 2021-10-15 20:45:03 UTC -9.8453 9.9153 1100000
NABRIVA THERAPEUTICS PLC NBRV 2021-10-15 20:15:03 UTC -9.8453 9.9153 1100000
NABRIVA THERAPEUTICS PLC NBRV 2021-10-15 19:45:03 UTC -9.8453 9.9153 1100000
NABRIVA THERAPEUTICS PLC NBRV 2021-10-15 19:15:04 UTC -9.8453 9.9153 1100000
NABRIVA THERAPEUTICS PLC NBRV 2021-10-15 18:45:03 UTC -9.8482 9.9182 1100000
NABRIVA THERAPEUTICS PLC NBRV 2021-10-15 18:15:03 UTC -9.8482 9.9182 1100000
NABRIVA THERAPEUTICS PLC NBRV 2021-10-15 17:45:03 UTC -9.8482 9.9182 900000
NABRIVA THERAPEUTICS PLC NBRV 2021-10-15 17:15:03 UTC -9.8482 9.9182 900000
NABRIVA THERAPEUTICS PLC NBRV 2021-10-15 16:45:03 UTC -9.8578 9.9278 900000
NABRIVA THERAPEUTICS PLC NBRV 2021-10-15 16:15:03 UTC -9.8578 9.9278 900000
NABRIVA THERAPEUTICS PLC NBRV 2021-10-15 15:45:03 UTC -9.8578 9.9278 900000
NABRIVA THERAPEUTICS PLC NBRV 2021-10-15 15:15:03 UTC -9.8578 9.9278 900000
NABRIVA THERAPEUTICS PLC NBRV 2021-10-15 14:45:02 UTC -9.8578 9.9278 900000
NABRIVA THERAPEUTICS PLC NBRV 2021-10-15 14:15:03 UTC -9.8578 9.9278 900000
NABRIVA THERAPEUTICS PLC NBRV 2021-10-15 13:45:03 UTC -9.8578 9.9278 900000
NABRIVA THERAPEUTICS PLC NBRV 2021-10-15 13:15:03 UTC -9.8578 9.9278 900000
NABRIVA THERAPEUTICS PLC NBRV 2021-10-15 12:45:03 UTC -9.8578 9.9278 900000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments